Skip to main content

Ira Klein, MD, MBA, FACP

Video thumbnail.
Videos
07/17/2023
CBEx Advisory Board Member Ira Klein, MD, VP of Medical Affairs for Tempus Labs, provides an inside look into featured session "AI in Cancer Care: Separating Fact from Fiction."
CBEx Advisory Board Member Ira Klein, MD, VP of Medical Affairs for Tempus Labs, provides an inside look into featured session "AI in Cancer Care: Separating Fact from Fiction."
CBEx Advisory Board Member Ira...
07/17/2023
Cancer Care Business Exchange
Transformative Employer Trends
09/19/2023
This installment of the Transformative Employer Trends column further explores ways to address access to gene and cell therapies that are transforming management of benefits by employer plans.
This installment of the Transformative Employer Trends column further explores ways to address access to gene and cell therapies that are transforming management of benefits by employer plans.
This installment of the...
09/19/2023
Journal of Clinical Pathways
Ira Klein, MD.
Videos
02/07/2024
Ira Klein, MD, MBA, vice president of medical affairs for Tempus Labs, provides insight into the future of AI in health care and how it will help cut down on mundane tasks and increase oncologists’ efficiency.
Ira Klein, MD, MBA, vice president of medical affairs for Tempus Labs, provides insight into the future of AI in health care and how it will help cut down on mundane tasks and increase oncologists’ efficiency.
Ira Klein, MD, MBA, vice...
02/07/2024
Journal of Clinical Pathways
Department
06/14/2018
Much has been written in the past few years on the growth of value-based contracting. Previous analyses have explored factors leading to success, advantages over standard contracting, and legislative and...
Much has been written in the past few years on the growth of value-based contracting. Previous analyses have explored factors leading to success, advantages over standard contracting, and legislative and...
Much...
06/14/2018
Journal of Clinical Pathways
Business of Pathways
09/13/2018
The current system of health care delivery and payment has tremendous inefficiencies that relate to an inability to share data among multiple parties, and from that sharing, glean useful and actionable information...
The current system of health care delivery and payment has tremendous inefficiencies that relate to an inability to share data among multiple parties, and from that sharing, glean useful and actionable information...
The...
09/13/2018
Journal of Clinical Pathways
Business of Pathways
11/18/2018
Population health, which encompasses the health outcomes of a specific group of individuals, has become an important concept in modern health care systems. Many public policy initiatives in recent years have included...
Population health, which encompasses the health outcomes of a specific group of individuals, has become an important concept in modern health care systems. Many public policy initiatives in recent years have included...
...
11/18/2018
Journal of Clinical Pathways
Business of Pathways
03/13/2019
Low-value health care continues to put stress on the US economy, as 20% to 40% of all health spending is designated as wasteful. To date, there have been few broad and sustained efforts to reign in wasteful spending....
Low-value health care continues to put stress on the US economy, as 20% to 40% of all health spending is designated as wasteful. To date, there have been few broad and sustained efforts to reign in wasteful spending....
...
03/13/2019
Journal of Clinical Pathways
Business of Pathways
04/16/2019
Many value-based payment agreements (VBAs) and programs incentivize physicians to provide care based on patients’ achievement of treatment targets, especially threshold-based metrics such as maintaining a...
Many value-based payment agreements (VBAs) and programs incentivize physicians to provide care based on patients’ achievement of treatment targets, especially threshold-based metrics such as maintaining a...
Many...
04/16/2019
Journal of Clinical Pathways
Business of Pathways
06/18/2019
Cell and gene therapies represent the next frontier of pharmaceutical development, holding the promise of delivering potentially curative therapies for diseases that have limited treatment options. However, these...
Cell and gene therapies represent the next frontier of pharmaceutical development, holding the promise of delivering potentially curative therapies for diseases that have limited treatment options. However, these...
Cell...
06/18/2019
Journal of Clinical Pathways
Business of Pathways
10/18/2019
*/ /*-->*/ While social media is all about sharing, very little personal preference data makes its way into health plan contracting around specific interventions and pathway programs today. As a result, the...
*/ /*-->*/ While social media is all about sharing, very little personal preference data makes its way into health plan contracting around specific interventions and pathway programs today. As a result, the...
...
10/18/2019
Journal of Clinical Pathways